A twenty-six week, randomized, open-label, 2-arm parallel group real world pragmatic trial to assess the clinical and health outcomes benefit of transition to Toujeo compared to standard of care insulin, in basal insulin treated patients with uncontrolled type 2 diabetes mellitus, with six month extension. - REGAIN CONTRO

sanofi-aventis Groupe0 个研究点目标入组 580 人开始时间: 2015年8月13日最近更新: 2017年12月11日

试验速览

暂无简介。

•Patients with type 2 diabetes insufficiently controlled (HbA1c >7%) with current (= 6 months) standard of care” basal insulin therapy (including insulin glargine U100, Levemir, NPH or Tresiba) with or without oral agents (metformin, sulfonylurea, thiazolidinedione, DPP-4 inhibitor, SGLT-2 inhibitor, glinides, alpha glucosidase inhibitors) and with or without use of a GLP-1 receptor agonist,
•Fasting plasma glucose (FPG) >130 mg/dL (7.2 mmol/L),
•Adult patients who have signed an Informed Consent Form (ICF) and privacy form(s).
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 400
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 180

•HbA1c =7%, no upper bound,
•Age <18 years,
•Type 1 diabetes mellitus,
•Any clinically significant abnormality identified on physical examination, laboratory tests, or vital signs at the time of screening, or any major systemic disease resulting in short life expectancy that in the opinion of the Investigator would restrict or limit the patient’s successful participation for the duration of the study,
•Use of any product containing short or rapid acting insulin since the time of diagnosis with type 2 diabetes mellitus other than temporary use during a pregnancy or hospitalization,
•Use of any product containing short or rapid acting insulin occurring within 3 months prior to the time of screening,
•Use of oral hypoglycemic agents other than those noted in the inclusion criteria, GLP-1 receptor agonists not approved for use with insulin, or any investigational agent (drug, biologic, device) within 3 months prior to the time of screening.
•All contraindications to standard of care” insulin therapy or warnings/precautions of use as displayed in the respective National Product labeling for these products.
•Hypersensitivity to insulin glargine or Toujeo excipients
•Pregnancy or lactation,
•Women of childbearing potential with no effective contraceptive method.

发起方